Potential Anticancer Mechanisms of a Novel EGFRDNA-Targeting Combi-Molecule (JDF12)‎ against DU145 Prostate Cancer Cells: An iTRAQ-Based Proteomic Analysis

Abstract EN

The development of multitargeting drugs is an emerging trend in cancer research.

To promote further development and clinical application of multitargeting drugs, this research was performed.

MTT assay and flow cytometry of Annexin V/propidium iodide staining were used to confirm the proapoptotic efficacy of a novel combi-targeting molecule, JDF12, against DU145 prostate cancer (PCa) cells.

Differentially expressed proteins between control and JDF12-treated cultures were revealed by isobaric tags for relative and absolute quantitation (iTRAQ), and part of them was confirmed by quantitative PCR.

Differentially expressed proteins were further analyzed for function, pathway association, and protein−protein interactions using GO, KEGG, and STRING databases.

A total of 119 differentially expressed proteins, 70 upregulated and 49 downregulated, were implicated in the anticancer effects of JDF12.

Many of these proteins are involved in biosynthesis, response to stress, energy metabolism, and signal transduction.

This study provides important information for understanding the anti-PCa mechanisms of JDF12, and well-designed combi-targeting drugs may possess stronger anticancer efficacy than single-targeting drugs and are thus promising candidates for clinical application.